American Healthcare REIT, Inc.
AHR
$55.73
-3.11%
American Healthcare REIT, Inc. is a healthcare-focused real estate investment trust that owns a diversified portfolio of clinical healthcare properties, including medical office buildings, skilled nursing facilities, senior housing, and hospitals. The company distinguishes itself as a specialized operator within the healthcare REIT sector, with a particular focus on integrated senior health campuses that generate the majority of its revenue. The current investor narrative centers on the company's strong operational momentum, highlighted by 16.4% NOI growth and a 93% share price surge over the past year, driven by improving occupancy, margin expansion, and institutional buying interest.…
AHR
American Healthcare REIT, Inc.
$55.73
Related headlines
AHR 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on American Healthcare REIT, Inc.'s 12-month outlook, with a consensus price target around $60.40 and implied upside of +8.4% versus the current price.
Average Target
$60.40
0 analysts
Implied Upside
+8.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$55 - $70
Analyst target range
AHR is covered by 15 analysts, with a consensus recommendation of 'Strong Buy' (mean score 1.4 out of 5, where 1 is Strong Buy). The average target price is $60.07, implying 4.6% upside from the current price of $57.44. The distribution leans heavily bullish, with recent upgrades from Citigroup (Buy from Neutral) and consistent Overweight/Outperform ratings from Barclays, Keybanc, and RBC Capital. The target range spans from $55.00 (low) to $70.00 (high), representing a 27.3% spread between low and high. The high target of $70.00 implies 21.9% upside and likely assumes continued NOI growth, margin expansion, and multiple expansion. The low target of $55.00 suggests a 4.2% downside, potentially pricing in slower growth or higher interest rate headwinds. The relatively tight spread (27.3%) indicates moderate conviction among analysts, while the strong buy consensus and recent upgrades signal positive sentiment. The absence of downgrades in recent months reinforces the bullish outlook.
Bulls vs Bears: AHR Investment Factors
AHR presents a compelling growth story with accelerating revenue, improving profitability, and strong free cash flow, supported by institutional buying and a Strong Buy analyst consensus. However, the stock's valuation is stretched at 112x trailing earnings, and the negative gross margin raises questions about cost control. The single most important tension is whether the company can sustain its revenue growth trajectory and expand margins to justify the premium valuation. If growth decelerates or margins fail to improve, the stock could face significant multiple compression. Currently, the bull case has stronger evidence given the operational momentum and analyst support, but the high valuation demands continued execution.
Bullish
- Accelerating Revenue Growth: Revenue grew 20.4% YoY in Q1 2026 to $650.8M, accelerating from 0.3% in Q4 2024 and 3.7% in Q2 2025. This strong momentum is driven by resident fees and services ($609.8M), indicating robust demand for senior housing.
- Profitability Turnaround: Net income swung from a loss of $6.8M in Q1 2025 to a profit of $23.7M in Q1 2026. Net margin improved from -1.3% to 3.6%, demonstrating successful operational leverage.
- Strong Free Cash Flow: Free cash flow TTM stands at $235.5M, up from $39.4M in Q1 2025. This provides ample liquidity for debt service and dividends, with interest coverage comfortably above 4x.
- Institutional Buying Interest: Recent news highlights a fund's new stake in AHR, citing 16.4% NOI growth and a 93% share price surge. Institutional demand signals confidence in the company's operational momentum.
Bearish
- Elevated Valuation Multiple: Trailing P/E of 112.0x is far above typical REIT multiples of 15-25x. Even the forward P/E of 66.8x implies high earnings expectations that leave little room for disappointment.
- Negative Gross Margin: Gross margin turned negative to -1.3% in Q1 2026, a sharp decline from 20.0% a year ago. Cost of revenue ($659.4M) exceeded revenue, indicating severe cost pressures.
- Low Liquidity Ratio: Current ratio of 0.37 suggests potential short-term liquidity risk. While operating cash flow covers interest, the low current ratio could be a concern if revenue growth stalls.
- Near 52-Week High: At $57.44, the stock is trading at 99% of its 52-week high ($58.02). This limits near-term upside and increases vulnerability to profit-taking or negative catalysts.
AHR Technical Analysis
AHR is in a sustained uptrend, with the stock price up 51.7% over the past year and currently trading at $57.44, representing 99.0% of its 52-week range (high $58.02, low $36.73). This positioning near the 52-week high suggests strong bullish momentum, though it also indicates the stock may be approaching overbought territory, warranting caution for new entries. The 1-year price change of 51.7% significantly outperforms the S&P 500's 16.5% gain, highlighting AHR's relative strength. Short-term momentum is accelerating, with a 1-month price change of 14.7% and a 3-month change of 14.7%, both outpacing the S&P 500's 0.8% and 3.5% returns, respectively. This acceleration aligns with the longer-term uptrend, confirming strong buying pressure. The relative strength index (RSI) is not provided, but the consistent upward movement suggests momentum is intact. Key support lies at the 52-week low of $36.73, while resistance is at the 52-week high of $58.02. A breakout above $58.02 would signal a continuation of the uptrend, potentially targeting new highs, while a breakdown below $36.73 would indicate a trend reversal. The stock's beta of 0.78 indicates lower volatility than the market, which may appeal to risk-averse investors but also implies less aggressive upside participation during rallies.
Beta
0.78
0.78x market volatility
Max Drawdown
-14.1%
Largest decline past year
52-Week Range
$38-$59
Price range past year
Annual Return
+46.6%
Cumulative gain past year
| Period | AHR Return | S&P 500 |
|---|---|---|
| 1m | +6.9% | -0.7% |
| 3m | +11.1% | +2.9% |
| 6m | +18.8% | +7.2% |
| 1y | +46.6% | +16.9% |
| ytd | +18.0% | +8.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AHR Fundamental Analysis
Revenue growth is accelerating, with Q1 2026 revenue of $650.8 million representing a 20.4% year-over-year increase, up from $540.6 million in Q1 2025. This marks a significant acceleration from the 0.3% growth seen in Q4 2024 (revenue of $542.7 million) and the 3.7% growth in Q2 2025. The primary revenue driver is resident fees and services, which totaled $609.8 million in the most recent quarter, indicating strong demand for senior housing and healthcare services. The growth trajectory supports the investment case for continued operational improvement and market share gains. Profitability has improved markedly, with net income turning positive to $23.7 million in Q1 2026, compared to a net loss of $6.8 million in Q1 2025. Gross margin, however, was negative at -1.3% in Q1 2026, a sharp decline from 20.0% in Q1 2025, likely due to higher cost of revenue ($659.4 million vs. $432.4 million). Operating margin improved to 6.5% from 7.4% in the prior year quarter, while net margin rose to 3.6% from -1.3%. The company is generating positive free cash flow of $49.7 million in Q1 2026, up from $39.4 million in Q1 2025. Free cash flow TTM stands at $235.5 million, providing ample liquidity for debt service and dividends. The debt-to-equity ratio is a conservative 0.51, and the current ratio of 0.37 suggests some liquidity risk, but operating cash flow of $88.1 million in Q1 2026 comfortably covers interest expenses of $18.8 million. ROE is 2.1%, reflecting modest profitability relative to equity.
Quarterly Revenue
$650774000.0B
2026-03
Revenue YoY Growth
+20.4%
YoY Comparison
Gross Margin
-1.3%
Latest Quarter
Free Cash Flow
$235490000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AHR Overvalued?
Given positive net income of $23.7 million, the trailing P/E ratio of 112.0x is the primary valuation metric. The forward P/E of 66.8x implies the market expects earnings growth, as the lower forward multiple suggests higher future earnings. The gap between trailing and forward P/E indicates anticipated earnings expansion, consistent with the improving profitability trend. Compared to the industry, AHR's P/S ratio of 3.46x is below the sector average (not provided), but the P/E of 112.0x appears elevated relative to typical REIT multiples, which often trade in the 15-25x range. The premium may be justified by the company's accelerating revenue growth and improving margins, but it also reflects high investor expectations. Historically, AHR's P/E has ranged from negative (due to losses) to over 190x in Q4 2025. The current trailing P/E of 112.0x is below the recent peak of 193.8x in Q4 2025 but above the 90.7x in Q1 2026. This suggests the stock is trading at a moderate premium to its own history, implying the market is pricing in continued improvement but not yet at extreme levels.
PE
112.0x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 32x~243x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
29.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: AHR's primary financial risk is its elevated valuation, with a trailing P/E of 112.0x that leaves little room for error. The negative gross margin of -1.3% in Q1 2026, down from 20.0% a year ago, signals cost pressures that could erode profitability if not reversed. While net income turned positive, the company's ROE of 2.1% is modest, and the current ratio of 0.37 indicates potential liquidity constraints, though operating cash flow of $88.1M comfortably covers interest expenses of $18.8M. Debt-to-equity of 0.51 is conservative, but the reliance on continued revenue growth to justify the valuation is a key vulnerability.
Market & Competitive Risks: The stock's beta of 0.78 suggests lower market correlation, but the premium valuation makes it sensitive to interest rate changes and sector rotation. Trading at 99% of its 52-week high, the stock is vulnerable to profit-taking. The healthcare REIT sector faces regulatory headwinds from potential Medicare/Medicaid reimbursement changes, which could impact tenant operators. Competitive pressures from other healthcare REITs and alternative senior housing providers could cap occupancy growth. The recent 93% share price surge over the past year has already priced in significant optimism, limiting upside from current levels.
Worst-Case Scenario: A combination of revenue growth deceleration (e.g., below 10%), margin compression from rising labor costs, and a broad market downturn could trigger a sharp re-rating. In this scenario, the stock could fall to its 52-week low of $36.73, representing a 36% decline from the current price of $57.44. This would imply a forward P/E of roughly 42x, still elevated but more in line with high-growth REITs. The worst-case loss of 36% is significant but not catastrophic, given the company's improving fundamentals and low debt.